Skip to main content

Table 1 Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol level of 170 mg/dL cut-off

From: Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy

  Entire patients (n = 244) High PCL group (n = 72) Low PCL group (n = 172) p value
Median (IQR) or Number (percent)
Age (y) 59.0 (52.0–68.0) 57.5 (52.0–67.0) 60.0 (51.3–68.8) 0.981
BMI (kg/m 2) 23.0 (21.0–24.8) 23.5 (21.8–42.8) 22.9 (20.8–24.9) 0.239
Sex (male) 185 (75.8%) 50 (69.4%) 135 (78.5%) 0.091
Serum Albumin (g/dL) 4.0 (3.5–4.3) 4.3 (3.9–4.4) 3.9 (3.4–4.2) < 0.001
Hemoglobin (g/dL) 12.1 (10.6–13.6) 13.1 (11.7–14.7) 11.8 (10.3–13.1) < 0.001
Platelet (k/dL) 274.5 (132.3–173.8) 271.5 (212.5–320.5) 299.8 (222.0–378.8) 0.038
PLC (mg/dL) 156.0 (132.3–173.8) 190 (178–205.8) 139.1 (126.3–157.8)  
Corrected calcium (mg/dL) 9.2 (8.9–9.7) 9.4 (9.0–9.8) 9.5 (8.8–9.6)  
ECOG score (≥2) 79 (32.4%) 22 (30.6%) 57 (33.1%) 0.765
Diabetes mellitus 60 (24.7%) 14 (19.7%) 46 (26.7%) 0.326
Hypertension 120 (49.6%) 33 (46.5%) 87 (50.9%) 0.574
Tumor size (cm) 8.0 (5.6–10.5) 6.5 (5.0–9.5) 8.7 (6.1–11.0) 0.407
Clinical stage (≥3) 138 (56.6%) 32 (44.4%) 106 (61.6%) 0.059
Metastatic sites     0.541
 Lung 78 (32.0%) 23 (31.9%) 55 (32.0%)  
 Liver 7 (2.7%) 1 (1.4%) 5 (2.9%)  
 Bone 24 (9.8%) 10 (13.9%) 14 (8.1%)  
 Non-regional LNI 2 (1.0%) 0 (0%) 2 (1.2%)  
 Adrenal gland 8 (3.3%) 4 (5.6%) 4 (2.3%)  
 Multiple metastasis 10 (4.1%) 3 (4.2%) 7 (4.1%)  
 Information missing 108 (44.3%) 33 (45.8%) 75 (43.6%)  
 Miscellaneous 2 (1.0%) 0 (0%) 2 (1.2%)  
Pathologic stage     0.060
 pT1 60 (24.6%) 24 (33.3%) 36 (20.9%)  
 pT2 36 (14.8%) 11 (15.3%) 25 (14.5%)  
 pT3 117 (48.0%) 33 (45.8%) 84 (48.8%)  
 pT4 31 (12.7%) 4 (5.6%) 27 (15.7%)  
Fuhrman grade     0.424
  ≤ 2 34 (13.9%) 12 (16.7%) 22 (12.8%)  
  ≥ 3 210 (86.1%) 60 (83.3%) 150 (87.2%)  
Histologic subtype     0.214
 Clear cell 213 (87.3%) 67 (93.1%) 146 (84.9%)  
 Papillary 13 (5.3%) 2 (2.8%) 11 (6.4%)  
 Chromophobe 4 (1.6%) 0 (0%) 4 (2.3%)  
 Collecting duct 5 (2.0%) 1 (1.4%) 4 (2.3%)  
 Unclassified 9 (3.7%) 2 (2.8%) 7 (4.1%)  
  1. IQR interquartile range, PCL preoperative cholesterol level, BMI body mass index, ECOG Eastern Cooperative Oncology Group, LNI lymph node invasion
\